Ahmed Daak

865 total citations
40 papers, 589 citations indexed

About

Ahmed Daak is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ahmed Daak has authored 40 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 22 papers in Hematology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Ahmed Daak's work include Chronic Lymphocytic Leukemia Research (14 papers), Platelet Disorders and Treatments (14 papers) and Hemoglobinopathies and Related Disorders (13 papers). Ahmed Daak is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Platelet Disorders and Treatments (14 papers) and Hemoglobinopathies and Related Disorders (13 papers). Ahmed Daak collaborates with scholars based in United States, United Kingdom and Sudan. Ahmed Daak's co-authors include Kebreab Ghebremeskel, Mustafa I. Elbashir, Mohamed A. El‐Sheikh, Ishag Adam, Mubarak S. Karsany, Miguel A. López‐Toledano, Michael A. Crawford, Adrián L. Rabinowicz, Matthew M. Heeney and David J. Kuter and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and American Journal of Clinical Nutrition.

In The Last Decade

Ahmed Daak

32 papers receiving 562 citations

Peers

Countries citing papers authored by Ahmed Daak

Since Specialization

Citations

This map shows the geographic impact of Ahmed Daak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed Daak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed Daak more than expected).

Fields of papers citing papers by Ahmed Daak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmed Daak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed Daak. The network helps show where Ahmed Daak may publish in the future.

Co-authorship network of co-authors of Ahmed Daak

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed Daak. A scholar is included among the top collaborators of Ahmed Daak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed Daak. Ahmed Daak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design 2025 ·Blood ·David J. Kuter, Quentin A. Hill, Bruno Fattizzo, Deepthi Jayawardene, Ahmed Daak	0
2	Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up 2025 ·Blood ·Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, (unknown), Catherine M. Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, (unknown), Deepthi Jayawardene, (unknown), Jing Zhao, Ahmed Daak, David J. Kuter	0
3	Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study 2025 ·American Journal of Hematology ·Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiřı́ Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F. Ypma, Vickie McDonald, (unknown), Milan Košťál, Isaac Goncalves, (unknown), Terry Gernsheimer, (unknown), (unknown), Ahmed Daak, David J. Kuter	3
4	Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study 2024 ·Blood ·Nichola Cooper, David J. Kuter, Henrik Frederiksen, (unknown), (unknown), Wilma Barcellini, Joan Cid, Catherine M. Broome, (unknown), Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M. Risitano, Sangeeta Sawhney, Quentin A. Hill, Deepthi Jayawardene, (unknown), J. Zhao, Ahmed Daak	6
5	Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia 2024 ·Blood Advances ·David J. Kuter, Jiřı́ Mayer, (unknown), (unknown), Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Robert Bird, Jaromír Gumulec, Milan Košťál, Terry Gernsheimer, Waleed Ghanima, Ahmed Daak, Nichola Cooper	11
6	Difficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN‐France registry 2024 ·British Journal of Haematology ·Guillaume Moulis, (unknown), (unknown), Matthieu Mahévas, Jean‐François Viallard, Thibault Comont, Stéphane Chèze, Sylvain Audia, Mikaël Ebbo, Louis Terriou, Jean‐Christophe Lega, Pierre‐Yves Jeandel, (unknown), (unknown), Ahmed Daak, Hikaru Okada, Bernard Bonnotte, Marc Michel, Maryse Lapeyre‐Mestre, Bertrand Godeau, (unknown)	4
7	Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease 2024 ·Blood ·Ahmed Daak, David R. Light, Fuad Abdulla, Chunsheng Chen, Julia Nguyen, (unknown), Michael Storek, Dimitry Ofengeim, Alexandra Hicks, Michelle Lee, Vincent Mikol, Gregory M. Vercellotti, John D. Belcher	1
8	P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR 2023 ·HemaSphere ·David J. Kuter, Nichola Cooper, (unknown), Ahmed Daak, Waleed Ghanima	0
9	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia 2020 ·Blood ·Catherine M. Broome, Alexander Röth, David J. Kuter, Marie Scully, Roy E. Smith, Jennifer Wang, Xiaoyu Jiang, Caroline Reuter, Ahmed Daak, William E. Hobbs	12
10	SC411 treatment can enhance survival in a mouse model of sickle cell disease 2020 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Celeste Yin‐Chieh Wu, Miguel A. López‐Toledano, Ahmed Daak, (unknown), (unknown), (unknown), Adrián L. Rabinowicz, Alireza Minagar, Jake T. Neumann, Reggie Hui‐Chao Lee, Hung Wen Lin	3
11	Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease 2020 ·Complementary Therapies in Medicine ·Ahmed Daak, Miguel A. López‐Toledano, Matthew M. Heeney	24
12	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 ·Blood Advances ·Ahmed Daak, Carlton Dampier, Beng Fuh, Julie Kanter, Ofelia Álvarez, (unknown), (unknown), Michael U. Callaghan, Alex George, Lynne Neumayr, Lee Hilliard, (unknown), Adrián L. Rabinowicz, Matthew M. Heeney	31
13	Omega-3 fatty acids are a potential therapy for patients with sickle cell disease 2018 ·Nature Reviews Disease Primers ·Ahmed Daak, Adrián L. Rabinowicz, Kebreab Ghebremeskel	7
14	The differential effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on seizure frequency in patients with drug-resistant epilepsy — A randomized, double-blind, placebo-controlled trial 2018 ·Epilepsy & Behavior ·(unknown), Kebreab Ghebremeskel, Manar E. Abdel‐Rahman, (unknown), (unknown), (unknown), (unknown), Ahlam A. Hamed, Adrián L. Rabinowicz, Mohamed Salih, Mustafa I. Elbashir, Ahmed Daak	15
15	Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance 2017 ·Clinical Therapeutics ·Kevin C. Maki, (unknown), William S. Harris, Mark Puder, Steven D. Freedman, Þorsteinn Thorsteinsson, Ahmed Daak, Adrián L. Rabinowicz, (unknown)	11
16	Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3–acid ethyl esters with an Advanced Lipid Technologies TM (ALT ® )–based formulation 2017 ·Journal of clinical lipidology ·Miguel A. López‐Toledano, Þorsteinn Thorsteinsson, Ahmed Daak, Kevin C. Maki, (unknown), Adrián L. Rabinowicz, (unknown)	20
17	Coagulation profile of Sudanese children with homozygous sickle cell disease and the effect of treatment with omega-3 fatty acid on the coagulation parameters 2017 ·PubMed ·(unknown), Ahmed Daak, Nazik Elmalaika Husain, Kebreab Ghebremeskel, Mustafa I. Elbashir	7
18	Sickle cell disease in western Sudan: genetic epidemiology and predictors of knowledge attitude and practices 2016 ·Tropical Medicine & International Health ·Ahmed Daak, (unknown), (unknown), Fatma A. Mohamed, Manar E. Abdel‐Rahman, Abozer Y. Elderdery, Octavious Talbot, Peter Kraft, Kebreab Ghebremeskel, Mustafa I. Elbashir, Wafaie Fawzi	43
19	Regular consumption of Nile river fish could ameliorate the low milk DHA of Southern Sudanese women living in Khartoum City area 2013 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·(unknown), Yoeju Min, Mahmoud A.O. Dawood, (unknown), Ahmed Daak, Kebreab Ghebremeskel	9
20	Effect of omega-3 (n−3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial 2012 ·American Journal of Clinical Nutrition ·Ahmed Daak, Kebreab Ghebremeskel, (unknown), (unknown), (unknown), Mustafa I. Elbashir, Michael A. Crawford	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact